Relevant Publications of the AABPMC and others
Relationships of vascular function with measures of ambulatory blood pressure variation
Atherosclerosis 2014; 233:48-54
Hodgson J, Woodman R, Croft K, Ward N, Bondonno C, Puddey I, Lukoshkova E, Head GA
Importance of ambulatory blood pressure in hypertension management.
Med J Aust.2012 Aug 6;197(3):143-4.
Head GA, McGrath BP, Nelson MR, Stowasser M.
Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement.
J Hypertens, 30, 253-266.
Head, G. A., McGrath, B. P., Mihailidou, A. S., Nelson, M. R., Schlaich, M. P., Stowasser, M., Brown, M. A., Mangoni, A. A., Cowley, D., Brown, M. A., Ruta, L.-A. & Wilson, A. National Heart Foundation and High Blood Pressure Research Council of Australia Ambulatory Blood Pressure Monitoring Consensus Committee
Objective: While most national guidelines for the diagnosis and management of hypertension emphasise that the initiation and modification of blood pressure (BP) lowering treatment should be related to absolute cardiovascular disease (CVD) risk, there is only limited information on how to incorporate ambulatory blood pressure (ABP) monitoring into this framework. The objective of this initiative is to provide ABP equivalents for BP cut points for treatment initiation and targets to be included into guidelines.
Methods: A critical analysis of the best available evidence from clinical trials and observational studies was undertaken to develop a new consensus statement for ABP monitoring.
Results: ABP monitoring has an important place in defining abnormal patterns of BP, particularly white-coat hypertension (including in pregnancy), episodic hypertension, masked hypertension, labile BP and nocturnal or morning hypertension. This consensus statement provides a framework for appropriate inclusion of ABP equivalents for low, moderate and high CVD risk patients. The wider use of ABP monitoring, while justified, is limited by its availability and cost due to the lack of medical subsidy in Australia. However, cost benefit analysis does suggest a cost saving in reduced numbers of inappropriate antihypertensive treatments.